SGR-1505
Investigational MALT1 inhibitor
Investigators interested in participating in this clinical program, please click below.
Our Approach
We leveraged Schrodinger's physics-based computational platform to rapidly identify novel MALT1 allosteric inhibitors with high potency, high specificity and other important drug-like properties. Multiple tumor models, including cell-derived and patient-derived xenograft models, confirmed the potent anti-tumor activity of these compounds, both alone and in combination with BTK inhibitors. In addition, preclinical data demonstrate strong anti-tumor activity of these inhibitors when evaluated in BTK resistant models of B-cell lymphomas. Clinical development candidate, SGR-1505, is currently in phase 1 clinical development for treating patients with relapsed or refractory B-cell neoplasms.
Clinical Trial Information
A Phase 1 clinical trial of SGR-1505 is ongoing to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary signals of therapeutic activity in patients with relapsed or refractory B-cell lymphomas.
A Phase 1 clinical trial is ongoing to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SGR-1505 in healthy subjects.
Expanded Access Statement
Schrödinger does not currently have an approved access program for our investigational products. We encourage patients to speak with their physicians about treatment options that may be right for them.
Presentations
Presented at: American Society of Hematology 2021 Annual Meeting
Presented at: American Society of Hematology 2020 Annual Meeting
Investigator Resources
Investigators interested in participating in this clinical program, please click below.
sdgr-trials-group@schrodinger.com
Independent Patient Resources
For more information about B-cell lymphomas, please visit:
